title: Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy.
abstract: A preliminary clinical study of renal allograft recipients revealed that a dimeric form of the human 80 kDa soluble receptor (sTNFR:Fc) for tumor necrosis factor (TNF) is well tolerated and attenuates the OKT3-induced acute clinical syndrome. The current study determined the in vivo biological effects and fate of sTNFR:Fc in these patients. Serial assessment of both antigenic and biological activities of circulating TNF and sTNFR:Fc have led to the following observations. (1) Although control patients typically responded to the first OKT3 injection with a rapid increase of biologically active TNFalpha, patients on sTNFR:Fc therapy had markedly higher serum TNFalpha antigenic levels, but no detectable bioactivity. Thus, sTNFR:Fc functioned as a potent antagonist, despite its cytokine-carrier effect. (2) Peak sTNFR:Fc levels averaging 800 and 2500 ng/ml were routinely achieved in vivo, using the low-dose (0.05 mg/kg) and high-dose (0.15 mg/kg) protocols. (3) The half-life of circulating sTNFR:Fc was estimated to be approximately 4.4 days, and levels of p80 receptors in treated patients remained significantly above those in control patients for at least 20 days. (4) In vitro blocking studies demonstrated that circulating sTNFR:Fc remained biologically active for 2 weeks. These results demonstrate that under current protocols, significant serum levels of sTNFR:Fc, capable of effectively neutralizing TNF activity over prolonged periods, can be achieved. The persistent OKT3 side effects observed, despite sTNFR:Fc therapy, are therefore likely to be caused by factors other than TNF.
authors.affiliation: Transplantation Unit, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: S
authors.initials: S
authors.lastname: Wee
authors.forename: M
authors.initials: M
authors.lastname: Pascual
authors.forename: J D
authors.initials: JD
authors.lastname: Eason
authors.forename: D A
authors.initials: DA
authors.lastname: Schoenfeld
authors.forename: J
authors.initials: J
authors.lastname: Phelan
authors.forename: S
authors.initials: S
authors.lastname: Boskovic
authors.forename: C
authors.initials: C
authors.lastname: Blosch
authors.forename: K
authors.initials: K
authors.lastname: Mohler
authors.forename: A B
authors.initials: AB
authors.lastname: Cosimi
mesh_terms: D019281:Dimerization; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D016853:Muromonab-CD3 / Q000009:adverse effects*; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis / Q000502:physiology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha